GLP-1 Market
LLY $1143.12 ▲ +0.0% NVO $37.54 ▲ +0.6% PFE $27.41 ▼ -1.4% VKTX $29.28 ▼ -2.2% KLRA $10.84 ▲ +4.3% GPCR $27.59 ▼ -0.3% RHHBY $52.51 ▲ +0.5%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Enicepatide

Company
Carmot Therapeutics, Inc.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
4 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

4 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 6, 2026

Find a Clinical Trial Near Me

See recruiting studies for Enicepatide and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07351045

    A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

    Not yet reported Hoffmann-La Roche 2000 participants Est. completion 2028-08-28 203 sites Stand-alone
    Other conditions: Obesity or Overweight
    View official trial listing →
  • Recruiting NCT NCT07351058

    A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

    Not yet reported Hoffmann-La Roche 1600 participants Est. completion 2028-08-07 204 sites Stand-alone
    Type 2 diabetes Other conditions: Obesity or Overweight
    View official trial listing →
  • Recruiting NCT NCT07626515

    A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese Participants

    Not yet reported Hoffmann-La Roche 36 participants Est. completion 2027-05-14 1 site Stand-alone
    Other conditions: Healthy Participants
    View official trial listing →
  • Recruiting NCT NCT07670416

    A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes

    Not yet reported Hoffmann-La Roche 300 participants Est. completion 2028-03-15 21 sites Stand-alone
    Type 2 diabetes Other conditions: Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT04838405

    A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus

    Not yet reported Carmot Therapeutics, Inc. 129 participants Est. completion 2024-08-02 2 sites Stand-alone
    Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT06525935

    A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

    Not yet reported Carmot Therapeutics, Inc. 469 participants Est. completion 2025-12-08 34 sites Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Active, not recruiting NCT NCT06628362

    A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

    Not yet reported Carmot Therapeutics, Inc. 447 participants Est. completion 2026-09-24 70 sites Stand-alone
    Type 2 diabetes Other conditions: Overweight or Obese
    View official trial listing →
  • Not yet recruiting NCT NCT07589686

    A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight

    Not yet reported Hoffmann-La Roche 486 participants Est. completion 2028-01-31 Stand-alone
    Other conditions: Obesity or Overweight
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Enicepatide, CT-388, RO7795068, RG6640

Related On The Pen coverage

The Weekly Dose & livestreams

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.